GlassScriptPhysician profile
Taylee M Eldridge
NPI 1386127660
$3,072.73
in general payments reported to CMS, 2019-2025
26 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $522 · 2023: $328 · 2024: $768 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.22 | 2021-2025 | |
| Ucb, INC. | $352.75 | 2022-2025 | Fintepla, Nayzilam, Briviact |
| Sk Life Science, INC. | $270.19 | 2023-2025 | Xcopri |
| Eisai INC. | $130.04 | 2024-2025 | |
| Lilly USA, LLC | $116.05 | 2023-2025 | Kisunla, Emgality, Reyvow |
| Argenx US, INC. | $102.00 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $100.14 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $84.54 | 2025 | Xeomin, Inbrija, Ampyra |
| Alexion Pharmaceuticals, INC. | $77.48 | 2022-2024 | Soliris, Ultomiris |
| Jazz Pharmaceuticals INC. | $66.81 | 2022-2023 | |
| Biogen, INC. | $63.91 | 2024-2025 | Tysabri, Vumerity, Skyclarys |
| Avanir Pharmaceuticals, INC. | $51.39 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $44.16 | 2025 | Crexont |
| Lundbeck LLC | $43.86 | 2024-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $40.02 | 2023 | Ongentys, Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $34.48 | 2022 | |
| Acadia Pharmaceuticals INC | $19.04 | 2025 | Nuplazid |
| Neurelis, INC. | $18.87 | 2024 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $17.88 | 2025 | Dysport |
| Genzyme Corporation | $17.24 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.11 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $16.42 | 2023 | Aptiom |
| Tanabe Pharma America, INC. | $15.98 | 2025 | Radicava |
| Teva Pharmaceuticals USA, INC. | $15.75 | 2022 | |
| Kyowa Kirin, INC. | $14.81 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylee Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.